Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 - 84 (Canceled).

(Currently amended) The polypeptide of claim $80\underline{101}$, wherein said circularly permutated β -lactamase protein consists of amino acids 26 to 288 of the following sequence prior to circular permutation

His Pro Glu Thr Leu Val Lys Val Lys Asp Ala Glu Asp Gln Leu Gly 26 30 35 40 Ala Arg Val Gly Tyr Ile Glu Leu Asp Leu Asn Ser Gly Lys Ile Leu 45 50 55 Glu Ser Phe Arg Pro Glu Glu Arg Phe Pro Met Met Ser Thr Phe Lys 60 65 70 Val Leu Leu Cys Gly Ala Val Leu Ser Arg Ile Asp Ala Gly Gln Glu 80 Gln Leu Gly Arg Arg Ile His Tyr Ser Gln Asn Asp Leu Val Glu Tyr 90 95 100 Ser Pro Val Thr Glu Lys His Leu Thr Asp Gly Met Thr Val Arg Glu 115 110 Leu Cys Ser Ala Ala Ile Thr Met Ser Asp Asn Thr Ala Ala Asn Leu 130 Leu Leu Thr Thr Ile Gly Gly Pro Lys Glu Leu Thr Ala Phe Leu His 140 145 Asn Met Gly Asp His Val Thr Arg Leu Asp Arg Trp Glu Pro Glu Leu 155 160 165

Asn Glu Ala Ile Pro Asn Asp Glu Arg Asp Thr Thr Met Pro Val Ala

170 180 175 185 Met Ala Thr Thr Leu Arg Lys Leu Leu Thr Gly Glu Leu Leu Thr Leu 190 195 200 Ala Ser Arg Gln Gln Leu Ile Asp Trp Met Glu Ala Asp Lys Val Ala 205 210 215 Gly Pro Leu Leu Arg Ser Ala Leu Pro Ala Gly Trp Phe Ile Ala Asp 220 225 230 Lys Ser Gly Ala Gly Glu Arg Gly Ser Arg Gly Ile Ile Ala Ala Leu 235 240 245 Gly Pro Asp Gly Lys Pro Ser Arg Ile Val Val Ile Tyr Thr Thr Gly 255 260 250 265 Ser Gln Ala Thr Met Asp Glu Arg Asn Arg Gln Ile Ala Glu Ile Gly

Ala Ser Leu Ile Lys His Trp

270

285

(SEQ ID NO: 2);

wherein said C-terminal break-point and said N-terminal break-point is between amino acid residues Glu 197 and Leu 198.

275

280

86-89 (Canceled).

90 (Currently amended) The polypeptide of claim 80100, wherein said first interactor domain and said second interactor domain bind to a single ligand, and and

wherein said circularly permutated TEM-1 β -lactamase protein is functionally reconstituted only upon binding of said first interactor domain and said second interactor domain to said ligand.

91 (Previously presented) The polypeptide of claim 90, wherein said ligand is comprised of an antigen fused to a second monomer of a hetero-dimerizing helix protein, said

Appl. No. 09/764,163 Amdt. dated October 28, 2008 Reply to Office Action of May 28, 2008

first interactor domain is an antibody, and said second interactor domain is a first monomer of a hetero-dimerizing helix, or

wherein said ligand is comprised of an antibody fused to a second monomer of a hetero-dimerizing helix protein, said first interactor domain is an antigen and said second interactor domain is a first monomer of a hetero-dimerizing helix and

wherein the first monomer of the hetero-dimerizing helix specifically binds to the second monomer of the hetero-dimerizing helix protein and the antibody specifically binds to the antigen.

92 (Previously presented) The polypeptide of claim 91, wherein the antibody is an scFv.

93-97 (Canceled).

- (Currently amended) The polypeptide of claim $80\underline{100}$, wherein the first interactor domain is fused through a first flexible polypeptide linker to the circularly permutated β -lactamase protein through the N-terminal break-point, and the second interactor domain is fused through a second flexible polypeptide linker to the circularly permutated β -lactamase protein through the C-terminal break-point.
- 99 (Previously presented) The polypeptide of claim 98, wherein said first polypeptide linker is 3-30 amino acids in length; and wherein said second polypeptide linker is 3-30 amino acids in length.
 - 100 (New) A polypeptide consisting essentially of:

a circularly permutated TEM-1 β -lactamase protein having an N-terminal fragment with a C-terminus and a C-terminal fragment with an N-terminus, a first interactor domain, and a second interactor domain;

wherein the first interactor domain is fused through the N-terminus of the C-terminal fragment, and the second interactor domain is fused through the C-terminus of the N-terminal fragment; and

Appl. No. 09/764,163 Amdt. dated October 28, 2008 Reply to Office Action of May 28, 2008

wherein the N-terminus and the C-terminus are located within a solvent exposed loop between amino acid residues Thr 195 and Ala 202; and

wherein the first interactor domain is selected from the group consisting of an antibody, an antigen, a first monomer of a hetero-dimerizing helix, a second monomer of a hetero-dimerizing helix, a receptor, a member of an expressed sequence library, and a member of a constrained peptide library; and

wherein the second interactor domain is selected from the group consisting of an antibody, an antigen, a first monomer of a hetero-dimerizing helix, a second monomer of a hetero-dimerizing helix, a receptor, a member of an expressed sequence library, and a member of a constrained peptide library;

wherein the circularly permutated TEM-1 β-lactamase protein is functionally reconstituted only upon binding of said first interactor domain to said second interactor domain.

101 (New) The polypeptide of claim 100, wherein the C-terminus of the N-terminal fragment is Glu 197 and the N-terminus of the C-terminal fragment is Leu 198.